CN105663772B - 一种治疗糖尿病的药物 - Google Patents
一种治疗糖尿病的药物 Download PDFInfo
- Publication number
- CN105663772B CN105663772B CN201610112968.2A CN201610112968A CN105663772B CN 105663772 B CN105663772 B CN 105663772B CN 201610112968 A CN201610112968 A CN 201610112968A CN 105663772 B CN105663772 B CN 105663772B
- Authority
- CN
- China
- Prior art keywords
- drug
- diabetes
- insulin
- radix
- yin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title claims abstract description 29
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 8
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 8
- 239000009636 Huang Qi Substances 0.000 claims abstract description 8
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 8
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 8
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 8
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 8
- 241001165494 Rhodiola Species 0.000 claims abstract description 7
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000843 powder Substances 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 239000002552 dosage form Substances 0.000 abstract description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002398 materia medica Substances 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 239000008103 glucose Substances 0.000 description 27
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 210000001124 body fluid Anatomy 0.000 description 14
- 239000010839 body fluid Substances 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 13
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 11
- 230000035922 thirst Effects 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 7
- 102100040918 Pro-glucagon Human genes 0.000 description 7
- 229940100389 Sulfonylurea Drugs 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 206010036067 polydipsia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940123208 Biguanide Drugs 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 229940123464 Thiazolidinedione Drugs 0.000 description 4
- 150000004283 biguanides Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 150000001467 thiazolidinediones Chemical class 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 description 2
- 229940123958 Short-acting insulin Drugs 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 240000005308 Juniperus chinensis Species 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000169594 Paropsia Species 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 108700006605 Val(8)- glucagon-like peptide 1 (7-36) Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于中成药物技术领域,具体涉及一种治疗糖尿病的药物。以仙鹤草、麦冬、黄芪、五味子、三七、石斛、葛根、红景天、栝楼根为原料,按照常规制备散剂的方法完成,具体为:将上述重量份数的诸药混合均匀后研末成120目的细粉,然后分装即可。其它剂型均可在此散剂的基础上浓缩加工而成。本发明提供调节糖代谢的中药制剂,经过理论与临床验证安全无毒、疗效显著,并且还具备制备简便、药源广泛、成本低廉等优点,尤其对糖尿病初期具有很好的效果。其临床有效率高达100%,治愈率达70%。
Description
技术领域
本发明属于中成药物技术领域,具体涉及一种治疗糖尿病的药物。
背景技术
糖尿病是由遗传和环境因素共同引起的一组以糖代谢紊乱为主要表现的临床综合征。胰岛素缺乏和胰岛素作用障碍单独或同时引起糖类、脂肪、蛋白质、水和电解质等的代谢紊乱,临床以慢性高血糖为主要特征,其进行并发症可有糖尿病酮症酸中毒、高渗性高血糖状态和乳酸性酸中毒。
大量流行病学资料表明,全世界糖尿病患者的数量迅速增加,包括中国在内的发展中国家尤为明显,糖尿病已经成为临床上的主要内分泌代谢病。2007~2008年,CDS在我国部分地区开展的糖尿病流行病学调查显示,在20岁以上的人群中,糖尿病患病率为9.7%,糖尿病前期的比例为15.5%,糖尿病患者中仅有40%获得诊断。据WTO估计,2005~2015年,中国由于糖尿病及相关心血管疾病导致的经济损失达5577亿美元。而近年的多项调查表明,无论是欧美发达国家还是包括中国在内的发展中国家,糖尿病控制状况均不容乐观。
目前西医治疗糖尿病主要采用口服降糖药物及胰岛素注射治疗。常用的口服药物包括磺脲类、双胍类、噻唑烷二酮类、非磺脲类促进胰岛素分泌剂、葡萄糖苷酶抑制剂和GLP-1六大类。
磺脲类(如格列本脲、格列吡嗪等)是最常用的口服降糖药之一,它们属于胰岛素促分泌剂,其主要作用机制作用于β细胞膜上的ATP敏感的钾通道,促进钙离子内流及细胞内钙离子浓度增高,从而刺激含有胰岛素的颗粒外移和胰岛素释放,使血糖降低。其促进胰岛素分泌作用不依赖于血糖浓度。磺脲类药物主要适用于新诊断的2型糖尿病患者,当用于1型糖尿病或晚期2型糖尿病患者β细胞功能衰竭时,往往无效。大量临床资料表明,磺脲类药物常见的副作用有低血糖反应、体重增加、皮肤过敏、消化系统受累和心血管系统损伤等。
双胍类药物(如二甲双胍)可不仅可抑制肝糖原的降解和肝内葡糖糖的输出,还可增强外周组织的胰岛素敏感性,从而增加对葡萄糖的摄取和利用而降低血糖。双胍类药物可以激化AMPK信号通路,从而发挥代谢调节的作用。然而,其常用的副作用有消化道受累、皮肤过敏反应、乳酸性酸中毒等。
噻唑烷二酮类药物(如吡格列酮、罗格列酮等)可激活PPARγ,增加靶组织对胰岛素的敏感性而降低血糖,此外它还可以改善脂代谢、改善血管内皮细胞功能。噻唑烷二酮类药物可促进脂肪的重新分布,常常导致体重增加和水肿,此外,噻唑烷二酮类药物还可增加骨折、心衰等糖尿病心血管事件的风险。
葡萄糖苷酶抑制剂(如阿卡波糖、伏格列波糖等)通过抑制α葡萄糖苷酶,从而延迟小肠粘膜对淀粉和糖类的吸收,从而降低餐后血糖,其最常见的副作用是如腹胀、腹泻等胃肠道不适。
非磺脲类促进胰岛素分泌剂(如瑞格列奈、那格列奈等)。瑞格列奈是苯甲酸的衍生物,使β细胞去极化,打开钙通道,使钙的流入增加,引过程诱导β细胞分泌胰岛素,其常见的不良反应为低血糖、视觉异常、胃肠道反应、肝酶升高和皮肤瘙痒、发红、荨麻疹等过敏反应。那格列奈是苯丙氨酸的衍生物,其作用机理主要为通过与胰岛β细胞上磺酰脲受体相结合,阻滞胰岛细胞ATP敏感钾通道开放,导致细胞膜去极化,引起钙通道开放,促进胰岛素分泌;它是一种新型的餐时血糖调节剂,能有效控制餐后血糖水平,然而其主要的副作用是服药后可有空腹感、冷汗、乏力、腹部帐满、腹痛、皮肤瘙痒等,个别病例出现乳酸、γ-GTP和GOT的升高。
GLP-1是由小肠L细胞分泌的一种肠促胰岛素的一类新型抗糖尿病药物。它可通过葡萄糖浓度依赖性方式促进胰岛β细胞分泌胰岛素,并减少胰岛α细胞分泌胰高血糖素,从而降低血糖,具有保护β细胞、葡萄糖浓度依赖性降糖作用及减轻体重的功效。除此之外,GLP-1还可能发挥降脂、降压作用及改善中枢学习记忆功能等其他生物学特性及功能。然而,天然的GLP-1很不稳定,绝大部分在体内可被二肽基肽酶IV从GLP-1的N末端倒数第二个氨基酸位点Ala8处迅速裂解形成GLP-1(9-36)或GLP-1(9-37)而失活,使其半衰期缩短至1~2分钟,必须持续静脉滴注或持续皮下注射才能产生疗效,这大大限制了GLP-1的临床应用。目前新研发的GLP-1类似物如Val8-GLP-1(7-36)、Exendin-4、Liraglutide、Lixisenatide等虽已经陆续从试验阶段步入临床应用,然而其胃肠道反应等其它诸多副作用仍在陆续被报导。
胰岛素治疗是目前控制高血糖的重要手段。1型糖尿病患者需依赖胰岛素维持生命,也必须使用胰岛素控制高血糖并降低糖尿病并发症的发生风险。2型糖尿病患者虽不需要胰岛素来维持生命,但当口服降糖药效果不佳或存在口服药使用禁忌时,仍需使用胰岛素,以控制高血糖并减少糖尿病并发症的发生危险。然而胰岛素注射可能出现低血糖、过敏反应、胰岛素性水肿和屈光失常等全身反应及注射局部皮肤红肿、发热及皮下有小结和皮下脂肪萎缩或增生等局部反应,长期使用胰岛素患者还可出现胰岛素抵抗。
由此可见,市面上销售的治疗糖尿病药物虽多,但存在副作用大、效果不佳等缺点。这些药物只能起到一时缓解病情的作用,并没有真正对于病因进行治疗,故疗效欠佳。
糖尿病属于中医消渴的范畴。消渴是以多饮、多食、多尿、身体消瘦为特征的一种疾病。消渴之名,首见于《黄帝内经》。东汉著名医家张仲景在《金匮要略》中将消渴分为三种类型:渴而多饮者为上消;消谷善饥者为中消;口渴、小便如膏者为下消。
中医认为,饮食不节、情志失调、劳欲过度、素体虚弱等因素均可导致消渴。该病的病机特征是阴虚燥热,以阴虚为本,以燥热为标,且两者互为因果:燥热甚者则阴虚越甚,阴虚甚者则燥热越甚。消渴的病变部位在肺、胃和肾,而以肾脏的病变为重。如果患者肺燥阴虚,津液失于滋润,则会出现口干舌燥、烦渴多饮的上消症状;若患者胃热炽盛,腐熟水谷的能力过盛,则会出现多食易饥的中消症状;若患者肾虚精亏,不能约束小便,则会出现尿频量多、尿浊如脂膏的下消症状;若患者兼有肺燥、胃热与肾虚的因素,则会同时出现多饮、多食、多尿等症状。
糖尿病的病程较长,该病患者的病情常常日久不愈,最终会因气阴两伤而合并出现其他病变。例如,患者若肺燥阴伤,可合并肺痨等病症,若肾阴亏耗,肝失滋润,可合并雀目、内障、耳聋等病症,若燥热内炽,蕴毒成脓,可合并疮疖、痈疽等病症,若阴虚燥热,炼液为痰,痰阻经络,可合并中风偏瘫或胸痹心痛等病症,等等。
在临床上,根据中医理论可将糖尿病分为肺热津伤型、胃热炽盛型、肾阴亏损型和阴阳两虚型。
发明内容
本发明的目的是针对目前在治疗糖尿病方面存在的诸多问题,通过中药滋阴润燥、补益肝肾、养心润肺、改善微循环、调节糖代谢,解决糖尿病患者血糖水平波动大、降低西药剂量及其副作用、防治其并发症,修复早期糖耐量受损,而提供一种治疗糖尿病的药物。
本发明为实现上述目的而采取的技术方案为:
一种治疗糖尿病的药物,是以下述重量份数的药物为原料药:
仙鹤草15~55、麦冬15~55、黄芪15~45、五味子6~25、三七3~20、石斛6~25、葛根10~45、红景天6~25、栝楼根12~50。
本发明组方中药物分析:本发明组方中仙鹤草,味苦、辛温,性平,无毒,归肺、肝、脾经。功能:止血、健胃,咯血、尿血、便血、赤白痢疾、崩漏带下、劳伤脱力、痈肿、跌打、创伤出血;麦冬,味甘、苦、寒,归肺、肾经,具有养阴润燥、清肺生津功能,主治肺燥干咳、顿咳痰粘、咽干口渴、肠燥便秘;黄芪,味甘,微温,归肺、脾、肝、肾经,补气固表,利尿托毒,排脓,敛疮生肌,气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚痿黄,内热消渴;五味子,味甘、酸、温,无毒,敛肺,滋肾,生津,收汗,涩精;三七,味甘、微苦,温,归肝、胃经,散瘀止血,消肿定痛;石斛,味甘淡、微咸、清润,归胃、肾经,益胃生津,滋阴清热,胃生津,滋阴清热,阴伤津亏,口干烦渴,食少干呕,病后虚热,目暗不明;红景天,味甘,涩,寒,归肺经,补气清肺,益智养心,收涩止血,散瘀消肿,主气虚体弱,病后畏寒,气短乏力,肺热咳嗽,咯血,白带腹泻,跌打损伤,烫火伤,神经症;栝楼根,味甘、微苦,微寒。归肺、胃经,清热泻火,生津止渴,消肿排脓;本发明组方中仙鹤草健胃,麦冬养阴润燥、清肺生津,黄芪补气固表,去虚热消渴,五味子滋肾生津,三七散瘀消肿,石斛益胃生津,红景天益智养心,栝楼根生津止渴,共同调理五脏六腑气血运行,布施津液于三焦,上焦如雾,以滋养脏腑官窍;下焦如渎,以化解淤腐,通利肠道,在外,散发经气,充养肌肤脂肪,使其保持弹性和活力。
而糖尿病患者绝大多数是阴虚燥热所致的津液生化失衡,因此本发明药物治疗糖尿病时以调达气血、生化津液、通调水道,在阴阳五行中健脾养胃,滋补肝肾,清心润肺,使水谷精微分布于乾坤表里,最关键的是恢复津液生化之源,正所谓为有源头活水来,水精四布,五经并行,合於四时五藏阴阳,揆度以为常也。
本发明的药物可制成任何一种药剂学上所说的剂型:如汤剂、片剂、丸剂、散剂、胶囊剂、颗粒剂、口服液等。本发明优选剂型为散剂。
本发明散剂的制备方法为:按照常规制备散剂的方法完成,具体为:将上述重量份数的诸药混合均匀后研磨成120目的细粉,然后分装即可。其它剂型均可在此散剂的基础上浓缩加工而成。
用法用量:开水冲服,每次20~60g,饭前服用,4次/天。
与现有技术相比,本发明提供调节糖代谢的中药制剂,经过理论与临床验证安全无毒、疗效显著,并且还具备制备简便、药源广泛、成本低廉等优点,尤其对糖尿病初期具有很好的效果。其临床有效率高达100%,治愈率达70%。
为进一步证实本发明的治疗效果,列举五例病例如下:
例一:陈某,男性,49岁,症见烦渴,能食善饥,尿频量多。化验:空腹血糖9.4mmol/L,餐后2h血糖12.6mmol/L,尿糖(+++)。在地医院经化验检查后确诊为2型糖尿病。该患者以口渴多饮为主,并伴有口干舌燥,边饮边渴,尿频量多,舌红少津,苔薄黄而干,多食易饥,形体消瘦,大便干燥,脉滑实有力。证属肺热津伤型。治疗此型糖尿病应以清热润肺、生津止渴为主,遂按上方用药水煎代茶饮服。连服3个月,查血糖、尿糖均正常。为巩固疗效,以每日一半药量,研末后水煎服用2月余。随访2年,未见复发。
例二:郭某,女性,42岁,查空腹血糖12.8mmol/L,经当地医院内分泌科确诊为2型糖尿病,中西医治疗后,效果欠佳,出现纳呆乏力,身体消瘦,以多食易饥为主,且伴有口渴、尿多、形体消瘦、大便燥结、舌红苔黄、脉滑数有力。治疗此型糖尿病应以清胃泻火、养阴增液为主,证属胃热炽热型,遂按上方用药水煎代茶饮服。连服2个月,症状好转,复查空腹血糖5.6mmol/L,继续按此方成分加减后用药3个月,血糖稳定在正常水平。
例三:伍某,男,57岁,会计员,患糖尿病5余年,长期口服格列本脲、盐酸苯乙双胍维持治疗,近三个月来,多饮多尿,手足无力,掌心潮热多汗,形体偏胖,并伴有尿浊如脂膏,或尿有甜味,腰膝酸软,乏力,头晕,耳鸣,口唇干燥,大便干结,皮肤瘙痒,小便频数,混浊如膏,面色黝黑,耳轮焦干,腰膝酸软,形寒畏冷,阳痿不举,舌淡苔白,脉沉细无力。证属肾阴亏损型,治疗此型糖尿病应以滋阴补肾、润燥止渴为主,血压在正常范围;尿糖(+++),空腹血糖11.2mmol/L,餐后2小时血糖16.8mmol/L,诊断为2型糖尿病,按此方连服4个月痊愈,嘱其适当饮食调节和运动,定期复查血糖。半年后随访,病情持续稳定,未在复发。
例四:王某,女性,59岁,采购员,确诊为糖尿病10余年,常年口服二甲双胍缓释片、阿卡波糖维持治疗,半年前出现视物模糊、四肢末端麻木疼痛,尿频量多且混浊如脂膏,同时伴有腰膝酸软,畏寒怕冷,形体消瘦,四肢欠温,面容憔悴,舌淡苔白而干,脉沉细无力。证属阴阳两虚型,治疗此型糖尿病应以温阳滋阴、补肾固涩为主,当地医院建议改用皮下注射短效胰岛素,12u/次,3次/天,联合皮下注射长效胰岛素,晚上睡前18u一次,肝肾功能正常,近三月血糖水平波动不稳定,偶感头晕、乏力,饥饿感不能耐受,空腹血糖2.5mmol/L~10.5mmol/L,餐后2小时血糖11.4mmol~18.5mmol/L,按此方连服15日,血糖水平接近正常范围,嘱其逐渐递减胰岛素剂量及注射频次,每日监测血糖变化,1个月后,皮下注射短效胰岛素,4u/次3次/天,联合皮下注射长效胰岛素,晚上睡前10u/次,每日配合饮食调节及适当运动(早晚各30分钟运动,汗出为止,也可以泡脚30分钟),3个月后停止短效胰岛素,每日晚上睡前皮下注射长效胰岛素8u,血糖水平稳定,不适症状消失,查近3个月糖化血红蛋白在正常范围,为巩固疗效药量减半后继续用药3个月后停用此方,只在晚上睡前长效胰岛素8u/天,嘱其每日适当运动,可根据血糖变化间断性使用此方成分加减,不适随诊,至今病情稳定。
例五:温某,男性,36岁,销售主管,因尿频、口干、体重下降明显,就诊于当地市医院,三天连查三次空腹血糖分别为8.5mmol/L、9.6mmol/L、8.9mmol/L,餐后2h血糖也均高于11.1mmol/L,为进一步确诊测糖化血红蛋白为7.1%,确诊为2型糖尿病,西医建议口服二甲双胍配合饮食控制,但患者工作繁忙,应酬较多,无法按时规律服药,血糖水平波动较大,因病人较年轻,患者及家属不愿长期打胰岛素,其后出现焦虑烦躁、失眠多梦,经朋友介绍,前来就诊,该患者以口渴、尿多、形体消瘦、神情疲倦、面色晦暗、舌苔淡白、脉沉细却有力为主要临床表现。证属混合型(胃热型和肾阴亏损型)。遂按上方用药研粉后开水冲服,暴饮暴食时可口服阿卡波糖片,连服1.5个月,口干、尿频等不适症状消失,间断测空腹血糖在4.5mmol/L~7.8mmol/L,继续按此方成分加减后用药3个月,血糖稳定在正常水平。
具体实施方式
实施例1
本实施例一种治疗糖尿病的药物,称取下述重量份数的原料药:
仙鹤草55g、麦冬55g、黄芪30g、五味子6g、三七3g、石斛15g、葛根10g、红景天6g、栝楼根12g。
本实施例散剂的制备方法为:按照常规制备散剂的方法完成,具体为:将上述重量份数的诸药混合均匀后研末成120目的细粉,然后分装即可。其它剂型均可在此散剂的基础上浓缩加工而成。
本发明药物的用法用量:开水冲服,每次20~60g,饭前服用,4次/天。
实施例2
仙鹤草15g、麦冬15g、黄芪15g、五味子25g、三七20g、石斛6g、葛根45g、红景天25g、栝楼根50g。
本实施例一种治疗糖尿病的药物,称取下述重量份数的原料药:
本实施例药物的具体制备方法及用法用量同实施例1。
实施例3
本实施例一种治疗糖尿病的药物,称取下述重量份数的原料药:
仙鹤草35g、麦冬35g、黄芪45g、五味子15g、三七12g、石斛25g、葛根20g、红景天15g、栝楼根30g。
本实施例药物的具体制备方法及用法用量同实施例1。
Claims (1)
1.一种治疗糖尿病的药物,其特征是,是以下述重量份数的药物为原料药:
仙鹤草15~55、麦冬15~55、黄芪15~45、五味子6~25、三七3~20、石斛6~25、葛根10~45、红景天6~25、栝楼根12~50。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610112968.2A CN105663772B (zh) | 2016-02-29 | 2016-02-29 | 一种治疗糖尿病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610112968.2A CN105663772B (zh) | 2016-02-29 | 2016-02-29 | 一种治疗糖尿病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105663772A CN105663772A (zh) | 2016-06-15 |
CN105663772B true CN105663772B (zh) | 2019-03-08 |
Family
ID=56305477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610112968.2A Active CN105663772B (zh) | 2016-02-29 | 2016-02-29 | 一种治疗糖尿病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663772B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113577202A (zh) * | 2021-09-13 | 2021-11-02 | 浙江理工大学 | 治疗糖尿病的铁皮石斛组合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1404852A (zh) * | 2001-08-20 | 2003-03-26 | 刘御广 | 治疗糖尿病的药物及其制备方法 |
CN101306149A (zh) * | 2007-05-19 | 2008-11-19 | 孙殿超 | 一种治疗糖尿病的药物 |
CN102641453A (zh) * | 2012-05-08 | 2012-08-22 | 鲍旭刚 | 一种治疗糖尿病的药物及其制备方法 |
CN104083640A (zh) * | 2014-08-04 | 2014-10-08 | 段希福 | 一种治疗糖尿病的中药组合物及其制备方法 |
-
2016
- 2016-02-29 CN CN201610112968.2A patent/CN105663772B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1404852A (zh) * | 2001-08-20 | 2003-03-26 | 刘御广 | 治疗糖尿病的药物及其制备方法 |
CN101306149A (zh) * | 2007-05-19 | 2008-11-19 | 孙殿超 | 一种治疗糖尿病的药物 |
CN102641453A (zh) * | 2012-05-08 | 2012-08-22 | 鲍旭刚 | 一种治疗糖尿病的药物及其制备方法 |
CN104083640A (zh) * | 2014-08-04 | 2014-10-08 | 段希福 | 一种治疗糖尿病的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105663772A (zh) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN108295211A (zh) | 一种治疗糖尿病的药食同源食品组方及其制备方法 | |
CN103041360B (zh) | 一种治疗功能性腹泻和肠易激综合征的口服液 | |
CN101125177A (zh) | 治疗糖尿病的醪酒 | |
CN104431772A (zh) | 一种润肠排毒面食制品及其制备方法 | |
CN105663772B (zh) | 一种治疗糖尿病的药物 | |
CN101530565B (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN109498731A (zh) | 一种治疗2型糖尿病脾肾气虚证的健脾益肾调糖丸及其制备方法 | |
CN102274396A (zh) | 治疗糖尿病肾病的中药及其制备方法 | |
CN102114185B (zh) | 一种治疗2型糖尿病胰岛素抵抗的药物 | |
CN102366480B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
LU501408B1 (en) | A coptis chinensis and atractlodis rhizoma based prescription for treating diabetes | |
CN100455317C (zh) | 治疗2型糖尿病的药物 | |
CN109010621A (zh) | 一种治疗糖尿病的中药组合物、制备方法及其应用 | |
CN109395045A (zh) | 一种治疗2型糖尿病湿热中阻证的清热化湿调糖丸及其制备方法 | |
CN107854588A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN101433589B (zh) | 一种治疗原发性小儿遗尿症的内服中药汤剂 | |
CN105770394A (zh) | 一种治疗糖尿病的药物 | |
CN105535195A (zh) | 一种治疗糖尿病的中药制剂及其制备方法及应用 | |
CN104606621A (zh) | 治疗ⅱ型糖尿病的中药制剂及制备方法 | |
CN102366550A (zh) | 一种治疗尿崩症的中药 | |
CN103599278A (zh) | 一种治疗糖尿病的中药 | |
CN116077608A (zh) | 一种治疗2型糖尿病的中药组合物、制剂及其制备方法 | |
CN108421024A (zh) | 治疗慢性便秘的中药方剂及其制备方法 | |
CN110652540A (zh) | 一种食积型消渴病的治疗配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200519 Address after: Room 103, floor 1, innovation and entrepreneurship training center, Shanxi Medical University, No. 1258, Xinjian North Road, Yuci District, Jinzhong City, Shanxi Province Patentee after: Shanxi Tangshu Pharmaceutical Technology Co., Ltd Address before: 037600 No. 16 West Street, Shuozhou, Shanxi, Yingxian County Co-patentee before: Zhang Shengxiao Patentee before: Yang Cheng |
|
TR01 | Transfer of patent right |